-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Tarsus Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2019 to Q4 2023.
- Tarsus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2023 was $0.000.
- Tarsus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2023 was $0.000.
- Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
- Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$4K, a 107% decline from 2021.
- Tarsus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $55K, a 5400% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)